.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practice

FDA: Expect Interchangeable Biosimilars Within 2 Years

July 4th 2017

By Jackie Syrop

Article

An FDA official has said that the agency expects interchangeable biosimilars to come to market within 2 years and that the first interchangeable biosimilar will likely be reviewed by an FDA advisory committee of outside experts.

Review Suggests Interchangeability Nearing for Single Switch Between Infliximab and Its Biosimilar

June 30th 2017

By Jackie Syrop

Article

Available data from comparative clinical trials and observational studies strongly confirm the equivalence between CT-P13 and originator infliximab for the treatment of rheumatologic diseases.

Practice

FDA: Expect Interchangeable Biosimilars Within 2 Years

Review Suggests Interchangeability Nearing for Single Switch Between Infliximab and Its Biosimilar

SCOTUS Ruling on 6-Month Notice Period for Biosimilars: Formulary and Cost Impact

The Future of Biosimilars and Managing Inflammatory Diseases

Clinician Awareness of Future Biosimilars

Challenges in Discussing Biosimilars With Patients

Formulary Considerations for Biosimilars

Variables Affecting Cost for Biosimilars

Cost and Prescribing Considerations for Biosimilars

Use of Biosimilars in Inflammatory Diseases